STRIVE: A Single-arm Phase 2 Study on Treatment of Lung Squamous Cell Carcinoma by Tiragolumab Plus Ivonescimab for Patients Who Progressed on Platinum Doublets and Anti-PD-1/PD-L1

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT07038915
Phase
PHASE2
Status
Withdrawn

Conditions

  • Anti-PD1/PDL1 Antibody
  • Lung Squamous Cell Carcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Tiragolumab — DRUG
    Given by IV
  • Ivonescimab — DRUG
    Given by IV

Study Details

To learn if the drug combination of tiragolumab and ivonescimab can help to control LSCC that got worse after standard treatment with platinum doublets and anti-PD-1/PD-L1 therapy.

Key Dates

Start date
Jul 28, 2025
Status verified
Jul 2025
Primary completion
Jul 28, 2025
Completion
Jul 28, 2025

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Single Arm
    Treatment with Tiragolumab + Ivonescimab

Primary Outcome Measure

Safety and adverse events (AEs). [ Time Frame: Through study completion; an average of 1 year ]

Related Studies